Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Duobody entities : Abbvie inc. save search
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
Published: 2023-12-09 (Crawled : 20:20) - prnewswire.com
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
| Email alert
Add to watchlist
CERE | $41.87 -0.29% -0.29% 630K
|
Finance
| Email alert
Add to watchlist
GNMSF | News | $290.34 3.83% 340
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
| Email alert
Add to watchlist
cd20 duobody antibody treatment response
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
Published: 2023-12-09 (Crawled : 20:20) - globenewswire.com
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
| Email alert
Add to watchlist
GNMSF | News | $290.34 3.83% 340
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
| Email alert
Add to watchlist
cd20 duobody antibody
AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Published: 2023-06-27 (Crawled : 23:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.0%
H: 0.43%
C: -0.07%
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
|
| O: -1.28%
H: 0.97%
C: 0.86%
cd20 duobody abbvie positive topline trial results
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Published: 2023-06-27 (Crawled : 23:00) - globenewswire.com
GNMSF | News | $290.34 3.83% 340
|
Health Technology
|
| O: 0.91%
H: 0.0%
C: -1.43%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.0%
H: 0.43%
C: -0.07%
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
|
| O: -1.28%
H: 0.97%
C: 0.86%
cd20 duobody abbvie positive topline trial results
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas
Published: 2022-12-11 (Crawled : 00:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.09%
H: 1.4%
C: 1.29%
cd20 duobody lymphomas meeting
U.S. FDA Accepts for Priority Review the Biologics License Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma
Published: 2022-11-21 (Crawled : 14:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.27%
H: 2.08%
C: 1.1%
cd20 duobody treatment fda application license review
AbbVie Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma (LBCL)
Published: 2022-10-28 (Crawled : 13:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -4.93%
H: 2.09%
C: 1.15%
cd20 duobody treatment
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
Published: 2022-10-28 (Crawled : 13:00) - globenewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -4.93%
H: 2.09%
C: 1.15%
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
|
| O: -0.03%
H: 1.82%
C: 1.82%
cd20 duobody treatment
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Published: 2022-07-18 (Crawled : 14:20) - globenewswire.com
GNMSF | News | $290.34 3.83% 340
|
Health Technology
|
| O: 0.15%
H: 4.93%
C: 2.47%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: 0.0%
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
|
| O: 0.82%
H: 1.15%
C: -1.16%
cd20 duobody treatment application authorization
AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress
Published: 2022-06-11 (Crawled : 16:20) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
| Email alert
Add to watchlist
cd20 duobody trial results
AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Published: 2022-04-13 (Crawled : 23:00) - prnewswire.com
GNMSF | News | $290.34 3.83% 340
|
Health Technology
|
| O: -0.14%
H: 3.21%
C: 1.5%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.69%
H: 3.81%
C: 2.83%
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
|
| O: -0.86%
H: 2.28%
C: -0.08%
cd20 duobody topline trial phase 1
Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Published: 2022-04-13 (Crawled : 22:00) - globenewswire.com
GNMSF | News | $290.34 3.83% 340
|
Health Technology
|
| O: -0.14%
H: 3.21%
C: 1.5%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.69%
H: 3.81%
C: 2.83%
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
|
| O: -0.86%
H: 2.28%
C: -0.08%
cd20 duobody topline trial phase 1
Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma
Published: 2022-03-08 (Crawled : 13:00) - globenewswire.com
GNMSF | News | $290.34 3.83% 340
|
Health Technology
|
| O: -0.14%
H: 5.36%
C: 5.36%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.29%
H: 0.6%
C: -1.24%
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
|
| O: -0.3%
H: 3.38%
C: 0.32%
cd20 duobody drug granted drug designation food grant designation
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.